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IMPORTANCE Glioblastoma is themost devastating primary malignancy of the central nervous
system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields
(TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell
division and organelle assembly.
OBJECTIVE To evaluate the efficacy and safety of TTFields used in combination with
temozolomidemaintenance treatment after chemoradiation therapy for patients with
glioblastoma.
DESIGN, SETTING, ANDPARTICIPANTS After completionof chemoradiotherapy, patientswith
glioblastomawere randomized (2:1) to receivemaintenance treatmentwith either TTFieldsplus
temozolomide (n = 466)or temozolomide alone (n = 229) (median time fromdiagnosis to
randomization, 3.8months inbothgroups). The studyenrolled695of theplanned700patients
betweenJuly2009andNovember2014at83centers in theUnitedStates,Canada,Europe, Israel,
andSouthKorea. The trialwas terminatedbasedon the results of this planned interimanalysis.
INTERVENTIONS Treatment with TTFields was delivered continuously (>18 hours/day) via 4
transducer arrays placed on the shaved scalp and connected to a portable medical device.
Temozolomide (150-200mg/m2/d) was given for 5 days of each 28-day cycle.
MAIN OUTCOMES ANDMEASURES The primary end point was progression-free survival in the
intent-to-treat population (significance threshold of .01) with overall survival in the
per-protocol population (n = 280) as a powered secondary end point (significance threshold
of .006). This prespecified interim analysis was to be conducted on the first 315 patients after
at least 18months of follow-up.
RESULTS The interim analysis included 210 patients randomized to TTFields plus
temozolomide and 105 randomized to temozolomide alone, and was conducted at a median
follow-up of 38months (range, 18-60months). Median progression-free survival in the
intent-to-treat population was 7.1 months (95% CI, 5.9-8.2 months) in the TTFields plus
temozolomide group and 4.0months (95% CI, 3.3-5.2 months) in the temozolomide alone
group (hazard ratio [HR], 0.62 [98.7% CI, 0.43-0.89]; P = .001). Median overall survival in the
per-protocol population was 20.5 months (95% CI, 16.7-25.0months) in the TTFields plus
temozolomide group (n = 196) and 15.6months (95% CI, 13.3-19.1 months) in the
temozolomide alone group (n = 84) (HR, 0.64 [99.4% CI, 0.42-0.98]; P = .004).
CONCLUSIONS AND RELEVANCE In this interim analysis of 315 patients with glioblastomawho
had completed standard chemoradiation therapy, adding TTFields to maintenance
temozolomide chemotherapy significantly prolonged progression-free and overall survival.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00916409
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G lioblastoma is the most devastating primary malig-nancy of the central nervous system in adults. Stan-dard treatment consists of maximal safe surgical re-
section or a diagnostic biopsy, followed by radiotherapy
(60 Gy) with concomitant daily temozolomide chemo-
therapy, and then maintenance treatment with temozolo-
midefor6to12months.1However,mostpatientswilldiewithin
1 to 2 years. Median progression-free survival from diagnosis
of 6.2 to 7.5 months and median overall survival from diag-
nosis of 14.6 to 16.7 months have been reported in clinical
trials.1-4 The reported2- and5-year survival rates5 are27%and
10%, respectively. During the last decade, all attempts to im-
prove the outcome for patients with glioblastoma have failed
when evaluated in large randomized trials.2-4,6,7
Tumor-treating fields (TTFields) are an antimitotic treat-
ment that selectively disrupts the division of cells by deliver-
ing low-intensity, intermediate-frequency (200 kHz) alter-
nating electric fields via transducer arrays applied to the
shaved scalp.8-10 In preclinical models, TTFields have been
shown to cause mitotic arrest and apoptosis by disrupting
mitotic spindle formation during metaphase and causing
dielectrophoretic movement of polar molecules during
cytokinesis.8,10-12 In a randomized phase 3 trial in which
TTFields were compared with chemotherapy in 237 patients
with recurrent glioblastoma, the use of TTFields did not pro-
long progression-free survival or overall survival, but the
therapy was associated with better quality of life without the
typical chemotherapy-associated toxic effects.13
Based on preclinical data demonstrating a synergistic
antitumor effect with chemotherapy and TTFields, and pilot
clinical feasibility data in combination with temozolomide,9
we initiated this phase 3 trial. The objective was to evaluate
the efficacy and safety of TTFields used in combination with
maintenance temozolomide in patientswith glioblastoma af-
ter initial treatment with temozolomide and radiotherapy.
Methods
Study Population
Patients eligible for this study (1) had histologically con-
firmed supratentorial glioblastoma (World Health Organiza-
tion grade IV astrocytoma14), (2) were progression-free after
havingundergonemaximal safe debulking surgerywhen fea-
sible or biopsy, and (3) had completed standard concomitant
chemoradiotherapywith temozolomide. Other eligibility cri-
teria were (1) age of 18 years or older, (2) Karnofsky Perfor-
mance Status (KPS) score of 70% or higher (the KPS score de-
scribes the general condition of a patient; a KPS score ≥70%
ensures some independence in activities of daily living), and
(3) adequate bone marrow, liver, and renal function.
Prioruseof implantedcarmustinewaferswasallowed.Pa-
tients with infratentorial tumor location and severe comor-
bidities were excluded. All patients provided written in-
formed consent before entering the study; the study was
approvedby the institutional reviewboardsor ethics commit-
tees of all 83 participating centers. The trial protocol appears
in Supplement 1.
Study Design and Treatment
This multicenter, open-label, randomized phase 3 trial was
designed to test the efficacy and safety of TTFields in com-
bination with temozolomide for treatment of glioblastoma
after initial treatment with chemoradiation. After the
completion of treatment with temozolomide and radio-
therapy, patients were randomized at a ratio of 2 to 1
(Figure 1) to receive standard maintenance temozolomide
chemotherapy (150-200 mg/m2/d for 5 days every 28 days
for 6-12 cycles according to the protocol1 from the European
Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups and theNational Cancer In-
stituteofCanadaClinical TrialsGroup)withorwithout the ad-
dition of TTFields. Treatment with TTFields was to be initi-
ated within 4 to 7 weeks from the last dose of concomitant
temozolomide and radiotherapy. Randomization was per-
formedthroughacentralweb-basedrandomizationsystemand
was stratified by extent of resection (biopsy, partial resec-
tion, gross total resection) and by O6-methylguanine-DNA
methyltransferase (MGMT) methylation status (methylated,
unmethylated, or unknown).
For patientswith available paraffin-embedded tumor tis-
sue, evaluation ofMGMT gene promoter methylation status
wasperformedasdescribedpreviously7,15,16 by a central labo-
ratoryblindedtotreatmentgroup(MDxHealth). IfMGMTmeth-
ylation status could not be determined centrally prior to ran-
domization, local MGMT methylation status was used for
stratification.
Patients in the TTFields plus temozolomide group
received continuous TTFields combined with standard main-
tenance temozolomide. Patients receiving TTFields had 4
transducer arrays placed on the shaved scalp and connected
to a portable device set to generate 200-kHz electric fields
within the brain (Optune, Novocure Ltd). Transducer array
layouts were determined using a mapping software system
for TTFields to optimize field intensity within the treated
tumor (NovoTAL, Novocure Ltd). After being trained to oper-
ate the device, the patient continued treatment at home. The
transducer arrays were supplied in sterile packaging and
replaced by the patient, a caregiver, or a device technician
twice per week. Although uninterrupted treatment was rec-
ommended, short treatment breaks for personal needs were
allowed.
If a patient experienced tumor progression, second-line
chemotherapywas offeredper local practice.However, in the
TTFields plus temozolomide group, TTFields could be con-
tinueduntil the second radiological progression,or clinical de-
terioration, for a maximum of 24 months.
Patient Surveillance and Follow-up
Baselinecontrast-enhancedmagnetic resonance imaging (MRI)
of the brainwas requiredwithin 2weeks before starting treat-
ment with maintenance temozolomide with or without
TTFields. A complete physical examinationwith collectionof
laboratory parameters was performedwithin 1 week of treat-
ment initiation. The evaluation also included a quality-of-life
questionnaire (QLQ-C30) that has a brain-specific module
(BN-20), whichwas developed by the EuropeanOrganisation
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for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups.17,18 A Mini-Mental State Examination
(a short bedside test used to evaluate cognition andmemory)
also was administered (a test result of 27-30 points is consid-
ered normal function).
Patientswere seenmonthly formedical follow-upandrou-
tine laboratory examinations. Quality of life was assessed ev-
ery 3 months. Magnetic resonance imaging was to be per-
formedeverysecondmonthafter thebaselineMRIuntil second
radiological progression in all patients. In the event of clini-
cal progression,MRIwas to be performedwithin 1 week after
the study investigator became aware of it. All MRIs were re-
viewed centrally by 2 blinded independent radiologists
(BioClinica Inc) and were evaluated for tumor response and
progressionusing the criteria developedbyMacdonald et al.19
In cases in which the central reviewers were not in agree-
ment, a third blinded radiologist adjudicated between them.
The third radiologist was involved in 17% of the cases in the
TTFields plus temozolomide group and in 18%of the cases in
the temozolomide alone group.
The results of the central reviewwere not communicated
to the study investigator, and all treatment decisions were
based on local imaging interpretation. Eight patients in the
TTFields plus temozolomide group (4%) comparedwith6pa-
tients in the temozolomide alone group (3%) were consid-
ered stable byblindedcentral review;however, treatmenthad
been changed by the study investigator due to local interpre-
tation of tumor progression. Patients were removed from the
progression-free survival analysis at the date of treatment
changewhen this occurredbefore evidenceof tumorprogres-
sion or when patients reached the cutoff date without tumor
progression.
Adverse eventswere recorded prospectively according to
the National Cancer Institute’s Common Terminology Crite-
ria (version 3.0) until 2 months after treatment discontinua-
tion.Adverseeventsarepresenteddescriptivelyasnumberand
percentageof patientswith eachadverse event term for all pa-
tients available at the time of the interim analysis. Treatment
adherence with TTFields was recorded electronically by the
device as average daily use in hours per day and information
was reviewed and transferred at themonthly follow-up visit.
Statistical Considerations
Theprimary endpointwasprogression-free survival in the in-
tent-to-treat (ITT) population assessedby an independent re-
viewpanel (80%power;hazard ratio [HR],0.78;2-sidedα level
Figure 1. Recruitment and Inclusion of Patients in the Study
1019 Patients signed informed consent
and were screened
324 Excluded
82 Progressive disease prior to randomization
53 Refused to participate (did not want to
be randomized)
46 Did not want to use the device
52 Did not meet eligibility criteria
20 Agreed to participate in another trial
4 Refused any further treatment
4 Could not tolerate temozolomide
chemotherapy
37 Other reasons
18 Lived too far away from study site
8 Did not complete radiotherapy and
temozolomide chemotherapy
695 Randomized
11 Withdrew consent
9 Lost to follow-up
8 Had clinical decline
5 Withdrew consent
4 Lost to follow-up
4 Had clinical decline
210 Completed ≥18 mo of follow-up 105 Completed ≥18 mo of follow-up
210 Included in interim primary analysis
196 Included in per-protocol analysis
14 Excluded
7 Never started treatment
1 Started other experimental treatment
6 Did not start second cycle of temozolomide
105 Included in interim primary analysis
84 Included in per-protocol analysis
21 Excluded
4 Never started treatment
1 Started other experimental treatment
5 Did not start second cycle of temozolomide
11 Crossed over and started tumor-treating
fields therapy
466 Randomized to receive tumor-treating
fields therapy plus temozolomide
229 Randomized to receive temozolomide alone
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of .05). The studywas also designed to have 80%power (HR,
0.76;2-sidedα levelof .05) toexamineoverall survival as a sec-
ondary end point. To avoid an increase in the risk of a false-
positive result, overall survival was to be tested statistically
only if the primary end point was met.
This prespecified interimanalysiswas tobeperformedaf-
ter the first 315 randomized patients reached a minimum
18-month follow-up.The final type I error rateof0.05was split
between the interim and final analyses based on a standard
α spending function.20-22 Theprotocol prespecified that over-
all survivalwouldbe analyzed in anas-treatedpopulation, ex-
cluding all patients in both treatment groups who (1) never
startedmaintenancetemozolomide, (2)hadmajorprotocolvio-
lations, (3) crossed over to the other treatment group, or
(4) received TTFields outside the protocol setting.
The primary end point would be achieved in the interim
analysis if progression-free survival in the ITTpopulationwas
significantly longer in the intervention group comparedwith
the control groupusinga stratified log-rank testwithanα level
of .01. The secondary end point would be achieved in the in-
terim analysis if overall survival in the as-treated population
(per-protocol population) was significantly longer in the
TTFields plus temozolomide group using a stratified
log-rank testwith an α level of .006. The confidence intervals
that go with the HRs are presented as 1 minus the prespeci-
fied α level for each analysis. For example, the α level in the
per-protocol interim analysis for overall survival was .006.
Therefore, thecorrespondingconfidence intervalused forpre-
senting the HRs was 1.000 − 0.006 (99.4% confidence inter-
val). Anupper confidence limit of less than 1 indicates thepre-
specified statistical threshold wasmet. An independent data
andsafetymonitoringcommitteewascharteredtostopthetrial
if the interim analysis of progression-free survival (ITT popu-
lation) and overall survival (per-protocol population) sur-
passed these predetermined thresholds, as well as for futility
or safety concerns.
In addition to these prespecified analyses, an analysis of
overall survival in the ITT population was performed. Fur-
thermore, a robustness analysis including all 695 patients en-
rolled in the trial served to validate the findings of the in-
terimanalysis (database lock:December 29, 2014; eAppendix
1 in Supplement 2).
Multiple imputation analyses alsowereperformed for the
trial’s primaryendpointofprogression-free survival in the ITT
population to test the sensitivity of the results to possible bias
using informative and interval censoring. These analyses in-
cluded (1) treating all patients with informative censoring as
treatment failures in the TTFields plus temozolomide group,
(2) censoring all patientswith informative censoring in the te-
mozolomide alone group (worst case scenario), and (3) treat-
ing all events in the TTFields plus temozolomide group and
in the temozolomide alone group as occurring differentially
at different periods during the inter-MRI interval before the
date of tumor progression.
All statistical analyses were performed using SAS version
9.4 (SAS Institute Inc) and R version 3.1.1.23 The final analysis
will be performedwhen all 695 patients enrolled in the study
haveat least 18monthsof follow-upandwill includeprespeci-
fied subgroup analyses and additional secondary end points,
including quality of life.
Results
Study Participants
Between July 2009 and November 2014, there were 695 pa-
tients with newly diagnosed glioblastoma randomized to re-
ceive either TTFields plus temozolomide (n = 466) or temo-
zolomidealone (n = 229).Data for the interimanalysis included
210 patients randomized to TTFields plus temozolomide and
105 to temozolomide alone (Figure 1; database lock: Septem-
ber5,2014).The independentdataandsafetymonitoringcom-
mitteemet inOctober 2014 to review the interimanalysis; the
trial met the predefined boundaries for success (improve-
ment of both progression-free and overall survival) and the
committee recommendedstudytermination, thusallowingpa-
tients in the control group to crossover and receive TTFields.
After approval of study termination by the US Food and
Drug Administration, the trial was closed to recruitment on
November 29, 2014, after 695patients of the planned 700pa-
tients had already been randomized. All patients in the con-
trol groupwith ongoingmaintenance therapywere offered to
receive TTFields. At the time of this report, 35 patients in the
control group crossed over to receive TTFields. Follow-up for
all patients continues according to the protocol.
Patient baseline characteristics were well balanced be-
tween the2groups (Table 1). Themedian agewas 57years and
66% were male. The median KPS score was 90%. Sixty-four
percentofpatientshadagross total resectionand 11%hadonly
adiagnosticbiopsy.Tumor tissue for centralMGMT testingwas
available for 72% of the patients; theMGMTmethylation fre-
quencywas 39% (75/191 valid tests; 39% for theTTFields plus
temozolomide group and 41% for the temozolomide alone
group). Tumor location in the brain was also comparable.
Carmustinewafers (Gliadel)wereusedat initial surgery in
2.4% of patients in the TTFields plus temozolomide group vs
2.9% of patients in the temozolomide alone group. Ninety-
five percent of the patients were white and 61%were treated
in the United States. The rest of the patients were treated at
centers in Canada, Europe, Israel, and South Korea. The me-
dian time from diagnosis to randomization was 3.8 months
(range, 2.0-5.7 months) for patients in the TTFields plus te-
mozolomidegroupand3.8months (range, 1.4-5.7months) for
those in the temozolomidealonegroup.Themedian time from
the end of treatmentwith temozolomide and radiotherapy to
randomization was 36 days in the TTFields plus temozolo-
midegroupand38days in the temozolomidealonegroup;53%
ofpatientswere randomizedafterhaving started the first cycle
of maintenance temozolomide. The median time from ran-
domization to initiation of TTFields was 5 days.
Treatment Delivery
All patients had completed radiotherapy and concomitant te-
mozolomide as per local practice. The median number of te-
mozolomide cycles until evidence of first tumor progression
was 6 cycles (range, 1-26 cycles) for patients in the TTFields
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plus temozolomide group and 4.0 cycles (range, 1-24 cycles)
for patients in the temozolomide alone group; themediandu-
ration of treatment with TTFields was 9 months (range, 1-58
months). Two-thirds (n = 141) of patients in the TTFields plus
temozolomide group continued treatment with TTFields af-
ter first tumor progression. Three-quarters (n = 157) of pa-
tients receiving treatment with TTFields were adherent to
therapy (ie, wearing the device >18 hours per day on average
during the first 3 treatment months).
Efficacy End Points
Asprespecified, the primary endpoint for the efficacy results
was based on progression-free survival in the ITT population
of the interim analysis data set. After a median follow-up of
38 months (range, 18-60 months), the median progression-
free survival fromrandomizationwas 7.1months (95%CI, 5.9-
8.2 months) in the TTFields plus temozolomide group com-
pared with 4.0 months (95% CI, 3.3-5.2 months) in the
temozolomide alone group (HR, 0.62 [98.7% CI, 0.43-0.89];
Table 1. Patient Baseline Characteristics and Treatment Details
All Patients
(N = 315)
TTFields Plus
Temozolomide
(n = 210)
Temozolomide
Alone
(n = 105)
Age, y
Mean (SD) 55.8 (11.1) 55.3 (11.3) 56.8 (10.5)
Median (range) 57 (20-83) 57 (20-83) 58 (21-80)
Karnofsky Performance Status score,
median (range), %a
90 (60-100) 90 (60-100) 90 (70-100)
Sex, No. (%)
Male 207 (66) 140 (67) 67 (64)
Female 108 (34) 70 (33) 38 (36)
Use at baseline, No. (%)
Antiepileptic medication 126 (40) 88 (42) 38 (36)
Corticosteroid therapy 77 (24) 51 (24) 26 (25)
Mini-Mental State Examination score,
No. (%)b
≤26 45 (15) 31 (15) 14 (13)
27-30 247 (78) 174 (83) 73 (70)
Unknown 23 (7) 5 (2) 18 (17)
Extent of resection, No. (%)
Biopsy 34 (11) 23 (11) 11 (10)
Partial resection 79 (25) 52 (25) 27 (26)
Gross total resection 202 (64) 135 (64) 67 (64)
Tissue available and tested, No. (%) 227 (72) 152 (72) 75 (71)
MGMT methylation 75 (33) 49 (32) 26 (35)
No methylation 116 (51) 79 (52) 38 (51)
Invalid test result 36 (16) 24 (16) 11 (15)
Region, No. (%)
United States 191 (61) 127 (60) 64 (61)
Rest of world 124 (39) 83 (40) 41 (39)
Completed radiation therapy, No. (%)
<57 Gy 18 (6) 13 (6) 5 (5)
60 Gy (standard; ±5%) 291 (92) 191 (91) 100 (95)
>63 Gy 6 (2) 6 (3) 0 (0)
Concomitant temozolomid use, No. (%)
Yes 308 (98) 207 (99) 101 (96)
Unknown 7 (2) 3 (1) 4 (4)
Time from event to randomization,
median (range), d
Last day of radiotherapy 37 (13-68) 36 (13-53) 38 (13-68)
Initial diagnosis 114 (43-171) 115 (59-171) 113 (43-170)
No. of maintenance temozolomide cycles until
first tumor progression, median (range)
6 (1-26) 6 (1-26) 4 (1-24)
Duration of treatment with TTFields,
median (range), mo
9 (1-58) 9 (1-58)
Adherence to TTFields therapy ≥75% during
first 3 mo of treatment
157 (75)
Abbreviations:MGMT,
O6-methylguanine-DNA
methyltransferase; TTFields,
tumor-treating fields.
a A higher score indicates better
functional status.
bA higher score indicates better
cognitive capability.
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stratified log-rankP = .001;Figure 2A). Thus, addingTTFields
to temozolomide treatment increased median progression-
free survival in the ITT population by 3.1 months.
As per the statistical analysis plan, overall survivalwas to
be tested in a prespecified per-protocol population only after
the primary end point was found to surpass the threshold for
significance in the interimanalysis.Medianoverall survival in
the per-protocol population was 20.5 months (95% CI, 16.7-
25.0 months) in the TTFields plus temozolomide group
(n = 196)comparedwith15.6months (95%CI, 13.3-19.1months)
in the temozolomide alone group (n = 84) (HR, 0.64 [99.4%
CI, 0.42-0.98]; stratified log-rank P = .004). The details on
the per-protocol population and analyses are summarized in
eAppendix 2 in Supplement 2.
In additional analyses in the ITT population, the median
overall survival was 19.6 months (95% CI, 16.6-24.4 months)
in theTTFields plus temozolomide group comparedwith 16.6
months (95%CI, 13.6-19.2months) in the temozolomidealone
group (HR,0.74 [95%CI,0.56-0.98]; stratified log-rankP = .03;
Figure 2B). The percentage of patients alive at 2 years follow-
ing enrollment was 43% in the TTFields plus temozolomide
group and 29% in the temozolomide alone group (P = .006).
To assess the robustness of the interim analysis findings,
additional analyses on all 695 patients randomized were per-
formed. Patient characteristics of all patients randomized
did not differ significantly from the interim data set, and the
results for the main end points were similar in these analy-
ses compared with the interim analysis (eAppendix 1 in
Supplement 2).
Second-line treatments, such as nitrosoureas, temozolo-
mide rechallenge, andbevacizumab,were receivedby67%of
the patients in the TTFields plus temozolomide group com-
paredwith 57% in the temozolomide alone group; about 40%
ofsecond-line therapies includedbevacizumabandabout40%
included nitrosoureas. The type of chemotherapy used at re-
currence was balanced between treatment groups.
Secondary imputation analyses of progression-free sur-
vivalwith relation to the effects of interval and informational
censoring did not change the conclusions of the primary pro-
gression-free survival analysis (eAppendix3 inSupplement2).
Safety and Tolerability
The addition of TTFields to temozolomide therapy in pa-
tientswith newly diagnosed glioblastomawas not associated
with any significant increase in systemic toxic effects com-
pared with temozolomide therapy alone (Table 2). The over-
all incidence,distribution, andseverityof adverseeventswere
similar in patients treated with TTFields plus temozolomide
and in those treated with temozolomide alone. The only no-
table exception was a higher incidence rate of localized skin
toxicity (medical device site reaction beneath the transducer
arrays) in patients treated with TTFields plus temozolomide.
Mild to moderate skin irritation was observed in 43% of pa-
tients treatedwithTTFieldsplus temozolomideandsevereskin
reaction (grade 3) in 2%. Mild anxiety, confusion, insomnia,
andheadacheswere reportedmore frequently in the patients
treatedwithTTFieldsplus temozolomideandoccurredmainly
at the timeof therapy initiation. The incidenceof seizureswas
almost identical in the 2 groups (15 [7%] in the TTFields plus
temozolomidegroupvs8 [8%] in temozolomidealonegroup).
A total of 12 patients died of causes considered unrelated to
treatmentwhile receivingadjuvant therapy (8 [3.9%] in the te-
mozolomide plus TTFields group and 4 [4.0%] in the temo-
zolomide alone group; Table 2).
Discussion
Glioblastoma is ahighly aggressive brain tumor affectingmen
andwomen, frequently at the peak of life. Prognosis remains
poor with no major treatment advance in more than a de-
cade. In the interim analysis of this randomized clinical trial,
Figure 2. Survival Curves for Patients Included in the Interim Analysis in the Intent-to-Treat Population
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HR, 0.62 (98.7% CI, 0.43-0.89); log-rank P = .001 HR, 0.74 (95% CI, 0.56-0.98); log-rank P = .03
1.0 1.0
Survival analyses on time from date of randomization until tumor progression,
death, or last follow-up (censored patients) according to the Kaplan-Meier
method. The small vertical ticks on the curves indicate censored patients.
HR indicates hazard ratio; TTFields, tumor-treating fields.
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the addition of TTFields to standard maintenance temozolo-
mide significantly improvedprogression-free andoverall sur-
vival. The prespecified analyses revealed that patients ran-
domized to receive TTFields plus temozolomide compared
withpatients randomized to receive temozolomide alonehad
amedianprogression-freesurvivalof7.1monthsvs4.0months
(ITT analyses). Patients who received TTFields plus temozo-
lomide had a median overall survival of 20.5 months com-
paredwith 15.6months in thosewho received temozolomide
alone (as per the prespecifed per-protocol analysis; the ITT
analysis did not differ substantially).
Based on the results of this planned interim analysis, the
trial’s independent data and safety monitoring committee
recommended termination of the trial. Because almost all
patients had been enrolled (695/700) in the study by the time
the recommendation was implemented, the full trial popula-
tion will be followed up for both progression-free and overall
survival. Subsequent analyses of all secondary end points
and subgroups will be performed when the follow-up data
are available.
The trial population and the results in the control group
in this study were comparable with other glioblastoma clini-
cal trials. Nevertheless, patients in this trialwere randomized
onlyafter theendof radiochemotherapy, and formost, the first
cycle of maintenance temozolomide had been started at the
time of randomization; thus, patients with early tumor pro-
gressionduring radiochemotherapywereexcluded.Most glio-
blastoma trials have reported survival from the date of initial
diagnosis or study enrollment before starting radiochemo-
therapy, thus 3 to 4months before randomization of the cur-
rent study.
When the interval from diagnosis to randomization is
added to the outcome results in this study, the progression-
free survival of 7.8months in the control group is comparable
with most other reported studies, and supports the general-
izability of these results. The Radiation Therapy Oncology
Group (RTOG) 0525 protocol randomized patients only after
the end of treatment with temozolomide and radiotherapy,
similar to our study.3 The control groups with standard dose
temozolomide only in these 2 trials were comparable: pro-
gression-free survival from randomization of 4.0 months in
the present study and 5.5 months in the RTOG 0525 trial and
overall survival of 16.6 months in both trials. Thus, the ben-
efit observedwithTTFields cannot be simply attributed topa-
tient selection. In thepresent trial, thegainof 3months inboth
median progression-free survival (from 4.0 months to 7.2
months; HR, 0.62) and median overall survival (from 16.6
months to 19.6 months; HR, 0.74), translating into a survival
gain at 2 years of 14% (from 29% to 43%) in the ITT popula-
tion is in the rangeofbenefit that is consideredclinicallymean-
ingful for therapeutic agents in oncology.
The prespecified analysis for overall survival in the in-
terim analysis was to be based on the per-protocol popula-
tion (n = 280); ie, removal in both study groups of the pa-
tients who did not start their second course of maintenance
temozolomide or had major protocol violations. This analy-
sis met the prespecified threshold for efficacy in the interim
analysis for the per-protocol population. In amore conserva-
tive analysis using the ITTpopulation, anoverall survival ben-
efit was also manifest. Furthermore, an analysis of robust-
nessperformedonall randomizedpatientsenrolledat the time
Table 2. Grade 3 to 4 Treatment-Emergent Adverse Events
No. (%) of Patients With Adverse Eventsa
TTFields Plus
Temozolomide
(n = 203)b
Temozolomide
Alone
(n = 101)c
Hematological disordersd 25 (12) 9 (9)
Anemia 1 (<1) 2 (2)
Leukopenia or lymphopenia 11 (5) 5 (5)
Neutropenia 6 (3) 1 (1)
Thrombocytopenia 19 (9) 3 (3)
Cardiac disorders 2 (1) 3 (3)
Eye disorders 2 (1) 1 (1)
Gastrointestinal disordersd 11 (5) 2 (2)
Abdominal pain 2 (1) 0
Constipation 2 (1) 0
Diarrhea 1 (<1) 2 (2)
Vomiting 3 (1) 1 (1)
General disorders 17 (8) 5 (5)
Fatigue 8 (4) 4 (4)
Infections 10 (5) 5 (5)
Injury and procedural
complicationsd
14 (7) 5 (5)
Fall 6 (3) 2 (2)
Medical device site reaction 4 (2) 0
Metabolism and nutrition
disorders
7 (3) 3 (3)
Musculoskeletal disorders 8 (4) 3 (3)
Nervous system disordersd 45 (22) 25 (25)
Seizure 15 (7) 8 (8)
Headache 4 (2) 2 (2)
Psychiatric disordersd 9 (4) 3 (3)
Anxiety 2 (1) 0
Bradyphrenia 0 1 (1)
Confusional state 2 (1) 1 (1)
Mental status changes 4 (2) 1 (1)
Psychotic disorder 2 (1) 0
Respiratory disorders 4 (2) 1 (1)
Skin disorders 0 1 (1)
Vascular disordersd 8 (4) 8 (8)
Deep vein thrombosis 1 (<1) 3 (3)
Pulmonary embolism 4 (2) 6 (6)
Abbreviation: TTFields, tumor-treating fields.
a Safety is reported on patients who have received any treatment. Randomized
patients who never received anymaintenance therapy were excluded from
this safety analysis.
b Eight patients died while receiving adjuvant therapy due to causes unrelated
to therapy (1 patient for each of the following reasons: cardiac events,
pulmonary emboli, respiratory, and infection; and 4 patients with central
nervous system disorders likely due to tumor progression).
c Four patients died while receiving adjuvant therapy due to causes unrelated to
therapy (1 patient for each of the following reasons: cardiac events, pulmonary
emboli, respiratory, and unknown).
d Patients may have hadmore than 1 adverse event so subcategories do not
total and not all events are subcategorized.
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of study termination (eAppendix 1 in Supplement 2) supports
the conclusions of the interim analysis.
This clinical trial has some important limitations. Patient
enrollment occurred only after the end of radiochemo-
therapy, leading to some variation in the delivery of standard
treatmentof temozolomideandradiotherapy.Patientswhohad
progressed early during radiochemotherapywere not eligible
for randomization, thusexcludingpatientswithverypoorprog-
noses. There is likely reporting bias for second-line therapies
after tumor progression because in the TTFields plus temo-
zolomidegroup,TTFieldswere tobecontinued,andthus,more
detailed treatment informationhasbeentracked for thisgroup.
This analysis reports a planned interim analysis on data
from the first 315 patients with at least 18 months of follow-
up; however, for detailed and meaningful subgroup analy-
ses, themature data of the full data set will be needed. Treat-
ment failure patterns, effects of second-line therapies, and
additionalmolecular analyses onbaseline tumorbiopsieswill
allow for better understanding of the clinical effects of this
novel treatment modality. With the last patient randomized
onNovember 29, 2014, however, these data are not expected
before the end of 2016.
This was an open-labeled study. A sham or placebo treat-
ment for the control group was considered neither practical
(patients would be able to sense heat when they were receiv-
ing TTFields) nor appropriate (due to the burden for patients
andcaregivers and theneed to shave the scalp andhave trans-
ducer arrays placed). In this respect, the trial resembles stud-
ies evaluating radiation therapy. This raises the question of a
placebo effect leading to the improved outcome. Although
some effect of placebo may be expected on subjective end
points, such as cognitive function and quality of life, objec-
tive end points, such as overall and progression-free survival
(assessed by a blinded review panel), are independent of pla-
cebo effects in cancer therapy.24 The panel did not have in-
formation on treatment received and no stigmata of TTFields
array pads were evident on MRI.
Recent randomized studies of patients with glioblas-
toma, which did not use placebo controls, failed to show any
increase in progression-free or overall survival3,7 despite in-
tensive treatment regimens requiring twice weekly hospital
visits.7 The magnitude of effect size seen in the present trial
(HR of 0.62 for progression-free survival and 0.74 for overall
survival) is beyond what could be attributed to a placebo ef-
fect. In addition, the support provided to patients in the
TTFieldsplus temozolomidegroupbydevice support special-
ists during the trialwas largely technical in nature anddidnot
include medical supportive care. Medical follow-up with
monthly visits was the same for both treatment groups.
Because TTFields were applied only to the head, an in-
crease in systemic adverse events was neither seen nor ex-
pected. No increase in seizure rate or neurological adverse
eventswas observed. Almost half of the patients treatedwith
TTFields did experience some grade 1 to 2 (mild tomoderate)
localized skin reaction related to the application of the trans-
ducer arrays used to deliver the TTFields. This adverse effect
couldbemanagedusingpublished skin care guidelines for pa-
tients receiving TTFields.25 Only 2% of patients receiving
TTFields had grade 3 to 4 (severe) skin reactions beneath the
transducer arrays.
Conclusions
In this interim analysis of 315 patientswith glioblastomawho
had completed standard chemoradiation therapy, adding
TTFields to maintenance temozolomide chemotherapy sig-
nificantly prolonged progression-free and overall survival.
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